Young, Asymptomatic People Can Get Reinfected With COVID-19 and Spread it More Than Once, Study Shows
A prospective study of 3,249 Marine recruits—who were mostly male and between the ages of 18 and 20—shows a significant risk of reinfection among those who have antibodies to SARS-CoV-2, the virus that leads to COVID-19. The study, posted on...
Researchers Identify a Promising New Antiviral Drug to Treat COVID-19
The search for better medical treatments for COVID-19 has led a team of scientists from the Icahn School of Medicine at Mount Sinai, with colleagues in San Francisco, to plitidepsin—a promising small molecule drug derived from a sea organism. When tested...
Sixth Annual Mount Sinai Innovation Awards
Individuals and teams from the Mount Sinai Health System were honored for advances in biomedical research, technology, and medicine at the sixth annual Mount Sinai Innovation Awards ceremony, a virtual event held Tuesday, December 8, 2020.Mount Sinai...
Mount Sinai Researchers Describe Viral Sanctuaries in the Gastrointestinal Tract of COVID-19 Patients
A new study published in the journal Nature by researchers at Mount Sinai in collaboration with two other labs at Rockefeller University and co-investigators from the California Institute of Technology and Weill Cornell Medicine describes for the first...
Mount Sinai Launches Global FREEDOM COVID Trial to Study Anticoagulant Therapies
Building on treatment protocols developed at the height of the COVID-19 pandemic, Mount Sinai Heart has launched the global FREEDOM COVID Anticoagulation Trial to determine the most effective dosage and regimen of anticoagulant therapy in improving the...
Ketamine Demonstrates Rapid Improvement in Patients With Post-traumatic Stress Disorder
Ketamine, an anesthetic found to help individuals with treatment resistant depression at lower doses, has now shown additional promise in easing the symptoms of post-traumatic stress disorder (PTSD), according to researchers at the Icahn School of Medicine...
Tracking SARS-CoV-2 and its Evolving Variants
A new variant of SARS-CoV-2, the virus that causes COVID-19, appeared in Great Britain in greater frequency in December and has been reported in New York State. The new variant appears to spread more rapidly than older ones and has a distinct set of...
Why Testing New Medicines in a Diverse Population Is Important
Companies are working to develop new vaccines for COVID-19, and one of the many challenges is ensuring that clinical trials required to test the new medicines reflect the population at large in order to determine how effective the vaccines will be when...
mRNA Vaccine Technology Makes Its Extraordinary Debut
The mRNA technology used to create the first two COVID-19 vaccines from Pfizer Inc., and Moderna, Inc. will undoubtedly change the course of vaccine development for years to come.Both companies have “shown that the vaccines are extraordinary,” says Peter...
